Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.51
SNY's Cash to Debt is ranked higher than
58% of the 1173 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. SNY: 0.51 )
SNY' s 10-Year Cash to Debt Range
Min: 0.14   Max: 10.62
Current: 0.51

0.14
10.62
Equity to Asset 0.58
SNY's Equity to Asset is ranked higher than
68% of the 983 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. SNY: 0.58 )
SNY' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.65
Current: 0.58

0.48
0.65
Interest Coverage 10.15
SNY's Interest Coverage is ranked higher than
55% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 133.58 vs. SNY: 10.15 )
SNY' s 10-Year Interest Coverage Range
Min: 7.88   Max: 19.65
Current: 10.15

7.88
19.65
F-Score: 7
Z-Score: 2.38
M-Score: -2.74
WACC vs ROIC
8.48%
15.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.44
SNY's Operating margin (%) is ranked higher than
87% of the 1117 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. SNY: 17.44 )
SNY' s 10-Year Operating margin (%) Range
Min: 15.25   Max: 38.21
Current: 17.44

15.25
38.21
Net-margin (%) 12.34
SNY's Net-margin (%) is ranked higher than
85% of the 1117 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.55 vs. SNY: 12.34 )
SNY' s 10-Year Net-margin (%) Range
Min: 7.92   Max: 25.8
Current: 12.34

7.92
25.8
ROE (%) 15.78
SNY's ROE (%) is ranked higher than
86% of the 1157 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.46 vs. SNY: 15.78 )
SNY' s 10-Year ROE (%) Range
Min: 5.18   Max: 33.55
Current: 15.78

5.18
33.55
ROA (%) 9.14
SNY's ROA (%) is ranked higher than
85% of the 1183 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.53 vs. SNY: 9.14 )
SNY' s 10-Year ROA (%) Range
Min: 2.62   Max: 21.59
Current: 9.14

2.62
21.59
ROC (Joel Greenblatt) (%) 77.45
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1178 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.83 vs. SNY: 77.45 )
SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 31.22   Max: 145.55
Current: 77.45

31.22
145.55
Revenue Growth (3Y)(%) -1.00
SNY's Revenue Growth (3Y)(%) is ranked higher than
62% of the 971 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. SNY: -1.00 )
SNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.5   Max: 27.4
Current: -1

-1.5
27.4
EBITDA Growth (3Y)(%) -4.40
SNY's EBITDA Growth (3Y)(%) is ranked higher than
65% of the 879 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. SNY: -4.40 )
SNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.4   Max: 35.7
Current: -4.4

-4.4
35.7
EPS Growth (3Y)(%) -8.20
SNY's EPS Growth (3Y)(%) is ranked higher than
65% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. SNY: -8.20 )
SNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -12.8   Max: 41.2
Current: -8.2

-12.8
41.2
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SNY Guru Trades in Q2 2014

Bill Nygren 4,950,000 sh (+90.38%)
PRIMECAP Management 3,011,646 sh (+21.59%)
Sarah Ketterer 567,921 sh (+12.04%)
Charles Brandes 2,182,305 sh (+5.28%)
James Barrow 28,526,802 sh (+2.65%)
John Buckingham 20,344 sh (+1.31%)
Manning & Napier Advisors, Inc 2,961,185 sh (+1.30%)
Ken Fisher 13,079,575 sh (+1.18%)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Mario Gabelli 4,500 sh (unchged)
John Hussman Sold Out
Dodge & Cox 43,549,909 sh (-0.26%)
HOTCHKIS & WILEY 9,772,061 sh (-0.33%)
First Eagle Investment 608,568 sh (-0.36%)
Third Avenue Management 13,402 sh (-14.67%)
Scott Black 178,985 sh (-27.57%)
NWQ Managers 2,602,503 sh (-52.34%)
» More
Q3 2014

SNY Guru Trades in Q3 2014

Manning & Napier Advisors, Inc 5,024,798 sh (+69.69%)
PRIMECAP Management 3,891,356 sh (+29.21%)
Bill Nygren 5,670,000 sh (+14.55%)
Sarah Ketterer 593,929 sh (+4.58%)
Charles Brandes 2,248,902 sh (+3.05%)
Mario Gabelli 4,580 sh (+1.78%)
John Buckingham 20,665 sh (+1.58%)
HOTCHKIS & WILEY 9,895,521 sh (+1.26%)
Ken Fisher 13,145,647 sh (+0.51%)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Scott Black 178,410 sh (-0.32%)
Dodge & Cox 43,267,004 sh (-0.65%)
James Barrow 28,293,723 sh (-0.82%)
NWQ Managers 2,409,040 sh (-7.43%)
Third Avenue Management 12,306 sh (-8.18%)
First Eagle Investment 34,157 sh (-94.39%)
» More
Q4 2014

SNY Guru Trades in Q4 2014

Steven Cohen 1,050,000 sh (New)
David Dreman 1,102 sh (New)
NWQ Managers 2,941,923 sh (+22.12%)
HOTCHKIS & WILEY 11,692,693 sh (+18.16%)
Charles Brandes 2,571,795 sh (+14.36%)
Mario Gabelli 5,195 sh (+13.43%)
PRIMECAP Management 4,287,207 sh (+10.17%)
James Barrow 30,804,459 sh (+8.87%)
John Buckingham 22,394 sh (+8.37%)
Manning & Napier Advisors, Inc 5,433,472 sh (+8.13%)
Murray Stahl 26,295 sh (+1.13%)
Dodge & Cox 43,272,800 sh (+0.01%)
Warren Buffett 3,905,875 sh (unchged)
First Eagle Investment 34,157 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Ken Fisher 13,085,033 sh (-0.46%)
Scott Black 176,460 sh (-1.09%)
Third Avenue Management 10,704 sh (-13.02%)
Sarah Ketterer 506,796 sh (-14.67%)
» More
Q1 2015

SNY Guru Trades in Q1 2015

Paul Tudor Jones 7,598 sh (New)
NWQ Managers 3,927,517 sh (+33.50%)
John Buckingham 24,608 sh (+9.89%)
HOTCHKIS & WILEY 11,782,180 sh (+0.77%)
Charles Brandes 2,573,969 sh (+0.08%)
Warren Buffett 3,905,875 sh (unchged)
David Dreman 1,102 sh (unchged)
Francis Chou 410,000 sh (unchged)
First Eagle Investment Sold Out
Third Avenue Management Sold Out
Steven Cohen Sold Out
Ken Fisher 13,058,095 sh (-0.21%)
Murray Stahl 26,185 sh (-0.42%)
Scott Black 175,625 sh (-0.47%)
Dodge & Cox 43,034,073 sh (-0.55%)
James Barrow 30,225,221 sh (-1.88%)
Sarah Ketterer 477,367 sh (-5.81%)
PRIMECAP Management 3,972,907 sh (-7.33%)
Mario Gabelli 4,700 sh (-9.53%)
Manning & Napier Advisors, Inc 2,499,440 sh (-54.00%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.40
SNY's P/E(ttm) is ranked higher than
83% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 58.60 vs. SNY: 27.40 )
SNY' s 10-Year P/E(ttm) Range
Min: 9.64   Max: 38.97
Current: 27.4

9.64
38.97
Forward P/E 7.85
SNY's Forward P/E is ranked higher than
99% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 7.85 )
N/A
PE(NRI) 27.20
SNY's PE(NRI) is ranked higher than
85% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 57.50 vs. SNY: 27.20 )
SNY' s 10-Year PE(NRI) Range
Min: 9.82   Max: 39.2
Current: 27.2

9.82
39.2
P/B 2.10
SNY's P/B is ranked higher than
80% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. SNY: 2.10 )
SNY' s 10-Year P/B Range
Min: 1.11   Max: 5.88
Current: 2.1

1.11
5.88
P/S 3.56
SNY's P/S is ranked higher than
65% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. SNY: 3.56 )
SNY' s 10-Year P/S Range
Min: 1.72   Max: 5.18
Current: 3.56

1.72
5.18
PFCF 15.20
SNY's PFCF is ranked higher than
94% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 701.67 vs. SNY: 15.20 )
SNY' s 10-Year PFCF Range
Min: 5.11   Max: 45
Current: 15.2

5.11
45
POCF 11.96
SNY's POCF is ranked higher than
92% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.21 vs. SNY: 11.96 )
SNY' s 10-Year POCF Range
Min: 4.15   Max: 23.37
Current: 11.96

4.15
23.37
EV-to-EBIT 20.12
SNY's EV-to-EBIT is ranked higher than
84% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.19 vs. SNY: 20.12 )
SNY' s 10-Year EV-to-EBIT Range
Min: 9.4   Max: 204.2
Current: 20.12

9.4
204.2
Shiller P/E 23.30
SNY's Shiller P/E is ranked higher than
91% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 23.30 )
SNY' s 10-Year Shiller P/E Range
Min: 11.32   Max: 25.52
Current: 23.3

11.32
25.52
Current Ratio 1.80
SNY's Current Ratio is ranked higher than
65% of the 1051 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. SNY: 1.80 )
SNY' s 10-Year Current Ratio Range
Min: 0.79   Max: 2.71
Current: 1.8

0.79
2.71
Quick Ratio 1.29
SNY's Quick Ratio is ranked higher than
63% of the 1051 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. SNY: 1.29 )
SNY' s 10-Year Quick Ratio Range
Min: 0.59   Max: 2.41
Current: 1.29

0.59
2.41
Days Inventory 156.14
SNY's Days Inventory is ranked higher than
67% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 145.57 vs. SNY: 156.14 )
SNY' s 10-Year Days Inventory Range
Min: 155.87   Max: 224.59
Current: 156.14

155.87
224.59
Days Sales Outstanding 74.40
SNY's Days Sales Outstanding is ranked higher than
77% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 91.38 vs. SNY: 74.40 )
SNY' s 10-Year Days Sales Outstanding Range
Min: 61.29   Max: 103.32
Current: 74.4

61.29
103.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.19
SNY's Dividend Yield is ranked higher than
89% of the 696 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. SNY: 3.19 )
SNY' s 10-Year Dividend Yield Range
Min: 1.41   Max: 5.46
Current: 3.19

1.41
5.46
Dividend Payout 0.84
SNY's Dividend Payout is ranked higher than
72% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 0.84 )
SNY' s 10-Year Dividend Payout Range
Min: 0.27   Max: 1
Current: 0.84

0.27
1
Dividend growth (3y) 3.80
SNY's Dividend growth (3y) is ranked higher than
71% of the 478 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. SNY: 3.80 )
SNY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 29.6
Current: 3.8

0
29.6
Yield on cost (5-Year) 4.08
SNY's Yield on cost (5-Year) is ranked higher than
89% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.51 vs. SNY: 4.08 )
SNY' s 10-Year Yield on cost (5-Year) Range
Min: 1.8   Max: 6.97
Current: 4.08

1.8
6.97
Share Buyback Rate -0.10
SNY's Share Buyback Rate is ranked higher than
84% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. SNY: -0.10 )
SNY' s 10-Year Share Buyback Rate Range
Min: 1.3   Max: -24.6
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 52.30
SNY's Price/Tangible Book is ranked lower than
63% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. SNY: 52.30 )
SNY' s 10-Year Price/Tangible Book Range
Min: 6.59   Max: 2093.5
Current: 52.3

6.59
2093.5
Price/DCF (Projected) 0.60
SNY's Price/DCF (Projected) is ranked higher than
98% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 0.60 )
SNY' s 10-Year Price/DCF (Projected) Range
Min: 0.48   Max: 1.02
Current: 0.6

0.48
1.02
Price/Median PS Value 1.30
SNY's Price/Median PS Value is ranked higher than
77% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. SNY: 1.30 )
SNY' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 2.65
Current: 1.3

0.63
2.65
Price/Peter Lynch Fair Value 5.00
SNY's Price/Peter Lynch Fair Value is ranked higher than
86% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 5.00 )
SNY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.47   Max: 4.01
Current: 5

0.47
4.01
Price/Graham Number 8.00
SNY's Price/Graham Number is ranked higher than
63% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.30 vs. SNY: 8.00 )
SNY' s 10-Year Price/Graham Number Range
Min: 1.88   Max: 6.42
Current: 8

1.88
6.42
Earnings Yield (Greenblatt) 5.10
SNY's Earnings Yield (Greenblatt) is ranked higher than
81% of the 1170 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. SNY: 5.10 )
SNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 10.6
Current: 5.1

0.5
10.6
Forward Rate of Return (Yacktman) 1.92
SNY's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.55 vs. SNY: 1.92 )
SNY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.1   Max: 60.3
Current: 1.92

1.1
60.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0O59.UK, SAN.France, SANF.Italy, SNW2.Germany, SNW.Germany, SANNV.France, SNYNF.USA, SNYN.Mexico, SAN.Switzerland,
Sanofi was incorporated under the laws of France on April 28,1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
» More Articles for NYSE:SNY

Headlines

Articles On GuruFocus.com
Dodge & Cox Stock Fund First Quarter 2015 Commentary Apr 24 2015 
Mt Stocks Apr 19 2015 
Scottrade Mar 22 2015 
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
Causeway Capital Global Value Equity Q4 2014 Commentary Feb 04 2015 
Causeway International Value Fund Q4 2014 Commentary Jan 20 2015 

More From Other Websites
Sanofi’s Global Head for Prostate Drug, Zhen Su, Leaves Company May 22 2015
​In Massachusetts, biotech firms account for a lot of value but few jobs May 22 2015
Amgen first to win EU backing for new kind of cholesterol drug May 22 2015
Amgen first to win EU backing for new kind of cholesterol drug May 22 2015
3 Top IBD 50 Stocks Hit New All-Time Highs May 21 2015
Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog May 21 2015
Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
Genzyme’s Announces Launch of Expression of Hope III Art Exhibit May 20 2015
Orexigen CEO Pledged To Keep Data Secret, But Not From Himself May 20 2015
Regeneron/Sanofi Announce Positive Data on Dupilumab - Analyst Blog May 19 2015
MannKind stock jumps on positive report about inhaled insulin May 19 2015
Amgen cholesterol drug could get EU green light this week May 19 2015
VCEL: Vericel Is Too Cheap To Ignore May 19 2015
5 Big Pharma Stocks to Trade for Breakout Gains May 19 2015
Genzyme Receives Innovation Award from the National Organization for Rare Disorders (NORD) for the... May 19 2015
MannKind's Huge Short Interest Sets Up Contrarian's Dream Buy May 19 2015
Sanofi and Regeneron Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the... May 18 2015
Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the... May 18 2015
5 Things MannKind's Management Wants You to Know May 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK